Followers | 686 |
Posts | 142466 |
Boards Moderated | 35 |
Alias Born | 03/10/2004 |
![](https://investorshub.advfn.com/uicon/35728.png?cb=1539773763)
Thursday, December 09, 2021 1:17:42 PM
By: Reuters | December 9, 2021
Drugstore operator CVS Health Corp (NYSE:CVS) said on Thursday it expects revenue from COVID-19 vaccination and testing to decline significantly next year, after it forecast 2022 adjusted earnings largely below estimates.
Shares of CVS, however, were up 3.8% at $96.7 after it raised its 2021 profit forecast to $8.00 per share from prior estimate of $7.90 to $8.00, with the company seeing higher-than-expected COVID-19 vaccine and testing sale volumes in the fourth quarter.
Pharmacy chains like CVS have benefited from distribution of COVID-19 vaccines and tests during the pandemic. CVS has so far administered 50 million vaccines and 29 million tests, which is expected to generate over $3 billion revenue in 2021.
CVS said it now assumes COVID-19 related revenue will decline 60%-70% next year, but added there were moving parts to the outlook given the uncertainty regarding new variants, booster doses and availability of oral antiviral medications and their impact on testing demand.
"You can make a bull case on vaccine and testing for next year based on what is happening and especially if we go into the mode of an annual booster kind of thing," Chief Financial Officer Shawn Guertin said at the company's Investor Day.
The company said it will revise this estimate once it has more data and clarity on policy.
The drugstore chain, which has seen its profit weighed down this year by higher medical costs in health insurer Aetna (NYSE:AET) due to the pandemic, expects COVID-19 to have a smaller impact on its insurance business next year.
CVS is still presuming COVID-19 will have a net negative impact next year, specifically in the Health Care Benefits segment, but will be significantly lesser than 2021, according to Guertin.
The company expects 2022 full-year adjusted profit between $8.10 and $8.30 per share, the midpoint of which was below analysts' estimates of $8.24.
Read Full Story »»»
![](http://studentaid.gov/universal-navigation/assets/us_flag_small.png)
Information posted to this board is not meant to suggest any specific action, but to point out the technical signs that can help our readers make their own specific decisions. Caveat emptor!
• DiscoverGold
Recent CVS News
- FDA Panel Supports Eli Lilly’s Donanemab, Rio Tinto Expands Stake in Boyne Smelters, and More News • IH Market News • 06/11/2024 11:11:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:30:57 PM
- CVS Health to present at the Bernstein 40th Annual Strategic Decisions Conference • PR Newswire (US) • 05/20/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 09:42:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 09:41:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 09:40:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 09:39:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 09:38:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 09:37:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 09:37:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 09:36:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 09:35:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 09:33:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 09:32:33 PM
- CVS Pharmacy® introduces Well Market™, a crave-worthy consumables brand • PR Newswire (US) • 05/16/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:19:18 PM
- CVS Health survey shows mental health concerns continue to rise • PR Newswire (US) • 05/09/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:40:04 PM
- Form 424B2 - Prospectus [Rule 424(b)(2)] • Edgar (US Regulatory) • 05/08/2024 08:34:36 PM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 05/07/2024 08:47:57 PM
- CVS Health to present at the Bank of America 2024 Healthcare Conference • PR Newswire (US) • 05/07/2024 08:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/07/2024 12:31:39 PM
- Perficient Stock Soars 52.9% Post-Acquisition; Luminar Declines 10% Amid Workforce Cutbacks, and Other News • IH Market News • 05/06/2024 12:09:00 PM
- CVS Health, Starbucks, Shares Weaker; Pinterest Soars • IH Market News • 05/01/2024 01:12:05 PM
- CVS HEALTH CORPORATION REPORTS FIRST QUARTER 2024 RESULTS AND REVISES FULL-YEAR 2024 GUIDANCE • PR Newswire (US) • 05/01/2024 10:30:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM